Clinical Lymphoma Myeloma and Leukemia This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

SOHO State of the Art Updates and Next Questions | Infections in Chronic Lymphocytic Leukemia Patients: Risks and Management
Although chronic lymphocytic leukemia (CLL) is a malignancy characterized by accumulation of tumor cells in the blood, bone marrow, lymph nodes and secondary lymphoid tissues, the hallmark of the disease and the major cause of death for patients with CLL is actually immune dysfunction and associated infections. Despite improvement in treatment based on combination chemoimmunotherapy and targeted treatment with BTK and BCL-2 inhibitors leading to longer overall survival for patients with CLL, the mortality due to infections have not improved over the last four decades. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 10, 2023 Category: Hematology Authors: Ernesto Gargiulo, Eduardo Flavio Oliveira Ribeiro, Carsten U. Niemann Tags: Review Article Source Type: research

SOHO State-of-the-Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions
Despite continued advances that have led to improved survival of patients with multiple myeloma (MM) over the years, MM remains largely incurable with overall survival in patients who have progressed after proteasome inhibitor, immunomodulatory drug, and anti-CD38 monoclonal antibody therapy measured in months. Better understanding of the immunopathology of MM has led to the discovery of newer treatment targets like B-cell maturation antigen (BCMA). BCMA is a tumor necrosis factor receptor superfamily expressed on normal B-lymphocytes and malignant plasma cells with a vital role in proliferation, maturation, and differenti...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2023 Category: Hematology Authors: Eden Biltibo, Jesus G. Berdeja Tags: Review Article Source Type: research

First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma: Recommendations from the Canadian Myeloma Research Group Consensus Guideline Consortium
Although the availability of effective novel treatments has positively impacted the quality of life and survival of newly diagnosed multiple myeloma (MM) patients, benefits in the transplant ineligible MM population may be limited by functional/frailty status.The Canadian Myeloma Research Group Consensus Guideline Consortium proposes consensus recommendations for the first-line treatment of transplant ineligible MM. To address the needs of physicians and people diagnosed with MM, this document further focuses on eligibility for transplant, frailty assessment, management of adverse events, assessment of treatment response, ...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2023 Category: Hematology Authors: Julie C ôté, Rami Kotb, Debra J. Bergstrom, Richard LeBlanc, Hira S. Mian, Ibraheem Othman, Martha L. Louzada Tags: Review Article Source Type: research

SOHO State of the Art Updates and Next Questions | BCMA-Directed CAR T-Cells: Early Results and Future Directions
Despite continued advances that have led to improved survival of patients with multiple myeloma (MM) over the years, MM remains largely incurable with overall survival in patients who have progressed after proteasome inhibitor, immunomodulatory drug, and anti- CD38 monoclonal antibody therapy measured in months. Better understanding of the immunopathology of MM has led to the discovery of newer treatment targets like B-cell maturation antigen (BCMA). BCMA is a tumor necrosis factor receptor superfamily expressed on normal B-lymphocytes and malignant plasma cells with a vital role in proliferation, maturation, and different...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2023 Category: Hematology Authors: Eden Biltibo, Jesus G. Berdeja Tags: Review Article Source Type: research

First Line Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma
Although the availability of effective novel treatments has positively impacted the quality of life and survival of newly diagnosed multiple myeloma (MM) patients, benefits in the transplant ineligible MM (TIMM) population may be limited by functional/frailty status.The Canadian Myeloma Research Group Consensus Guideline Consortium (CMRG-CGC) proposes consensus recommendations for the first-line treatment of TIMM. To address the needs of physicians and people diagnosed with MM, this document further focuses on eligibility for transplant, frailty assessment, management of adverse events, assessment of treatment response, an...
Source: Clinical Lymphoma, Myeloma and Leukemia - February 3, 2023 Category: Hematology Authors: Canadian Myeloma Research Group Consensus Guideline Consortium, Canadian Myeloma Research Group, Myeloma Canada Tags: Review Article Source Type: research

SOHO State of the Art Updates and Next Questions | Hyper-CVAD in 2022: Lessons Learned and New Approaches
Combination chemotherapy is the mainstay of treatment for acute lymphoblastic leukemia (ALL). The Hyper-CVAD regimen was developed in 1992 at MD Anderson Cancer Center and has since become a standard of care option for adult patients with ALL. Since its conception, a number of modifications have been implemented to customize the regimen for different patient populations and safely incorporate novel therapies without compromising tolerability. We aim to review the evolution of the Hyper-CVAD regimen over the past 3 decades, focusing on clinical pearls, as well as future directions. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - February 1, 2023 Category: Hematology Authors: Caitlin R. Rausch, Hagop M. Kantarjian, Elias J. Jabbour Tags: Review Article Source Type: research

Impact of Race and Age and their Interaction on Survival Outcomes in Patients with Diffuse Large B-Cell Lymphoma
Advances in treatment for patients with Diffuse Large B-Cell Lymphoma (DLBCL) have led to improved patient outcomes but the magnitude of these disparities remains understudied with regards to improved survival outcomes. We sought to describe changes in DLBCL survival trends over time and explore potential differential survival patterns by patients ’ race/ethnicity and age. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2023 Category: Hematology Authors: Kira MacDougall, Silas Day, Spencer Hall, Daniel Zhao, Manu Pandey, Sami Ibrahimi, Mohamad Khawandanah, Jennifer Holter Chakrabarty, Adam Asch, Ryan Nipp, Taha Al-Juhaishi Tags: Original Study Source Type: research

Characteristics and Outcomes of Older Patients with Classical Hodgkin Lymphoma: An Australasian Lymphoma Alliance, and Lymphoma and Related Diseases Registry Study
There is no standard front-line therapy for older patients with classical Hodgkin lymphoma (cHL). We analysed the clinical presentation and front-line management of older Australian patients with cHL and explored factors associated with unplanned hospital admission and survival. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 31, 2023 Category: Hematology Authors: Zhong Goh, Maya Latimer, Katharine L. Lewis, Chan Y. Cheah, Pietro Di Ciaccio, Tania Cushion, Eliza A. Hawkes, Sean Harrop, Matthew Ku, Ashlea Campbell, Nada Hamad, Erica M. Wood, Eliza Chung, Pin-Yen Chen, Tara Cochrane Tags: Original Study Source Type: research

Distinctive attributes of Indian patients with classical BCR::ABL1 negative myeloproliferative neoplasms: Unified clinical and laboratory data
We report one of the largest single centre data from a mixed referral setting in India describing baseline characteristics and outcomes of patients with classical BCR::ABL1 negative MPNs. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 27, 2023 Category: Hematology Authors: Suvir Singh, Jagdeep Singh, Arpan Mehta, Rintu Sharma, Kaveri Joshi, Kunal Jain, Davinder Paul, Gurleen Oberoi, Nandita Jindal, Barjinderjit Dhillon, Vikram Narang Tags: Original Study Source Type: research

Editorial Board
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 25, 2023 Category: Hematology Source Type: research

Table of Contents
(Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 25, 2023 Category: Hematology Source Type: research

SOHO State of the Art Updates and Next Questions | Accelerated Phase of MPN: What It Is and What to Do About It
Progression of Philadelphia-chromosome negative myeloproliferative neoplasms (MPNs) to the accelerated phase (AP) or blast phase (BP) is associated with poor outcomes. As our understanding of the molecular drivers of MPN progression has grown, there has been increasing investigation into the use of novel targeted approaches in the treatment of these diseases. In this review we summarize the clinical and molecular risk factors for progression to MPN-AP/BP followed by discussion of treatment approach. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 25, 2023 Category: Hematology Authors: Anand A. Patel, Olatoyosi Odenike Tags: Review Article Source Type: research

Yttrium-90 Ibritumomab Tiuxetan is Cost-Effective Compared to Bendamustine  + Rituximab in Low-grade Lymphomas
The study aimed to determine the cost-effectiveness of Yttrium-90 ibritumomab tiuxetan [(90)Y-IT] in the first-line treatment of low-grade lymphoma compared to bendamustine + rituximab (BR). There were no differences in response rates or 5-years progression-free survival between the two groups. Patients who received (90)Y-IT had fewer oncology clinic visits, days of therapeutic use, and 40% less use of growth factorsThe aim of our study is to determine the cost-effectiveness of Yttrium-90 ibritumomab tiuxetan [(90)Y-IT] in the first-line treatment of low-grade follicular lymphoma (LG-FL) and marginal zone B cell lymphoma (...
Source: Clinical Lymphoma, Myeloma and Leukemia - January 25, 2023 Category: Hematology Authors: Muhamad Alhaj Moustafa, Bijan J. Borah, James P. Moriarty, Ruchita Dholakia, Liuyan Jiang, Ke Li, Thomas E. Witzig, Bradford S. Hoppe, Jennifer Peterson, James R. Cerhan, Han W Tun Tags: Original Study Source Type: research

Yttrium-90 Ibritumomab Tiuxetan is Cost-effective compared to Bendamustine  + Rituximab in low-grade Lymphomas
Yttrium-90 ibritumomab tiuxetan [(90)Y-IT] is a CD20-targeted radio-immunotherapeutic agent. It has shown an excellent therapeutic activity with high tolerability against previously untreated follicular lymphoma (FL) and marginal zone B cell lymphoma (MZL). It is an attractive therapeutic option as the treatment schedule is short and convenient. The aim of our study is to determine the cost-effectiveness of (90)Y-IT in comparison to the standard-of-care Bendamustine  + Rituximab (BR) in the first-line treatment of low-grade FL (LG-FL) and MZL in the real world. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 25, 2023 Category: Hematology Authors: Muhamad Alhaj Moustafa, Bijan J. Borah, James P. Moriarty, Ruchita Dholakia, Liuyan Jiang, Ke Li, Thomas E. Witzig, Bradford S. Hoppe, Jennifer Peterson, James R. Cerhan, Han W Tun Tags: Original Study Source Type: research

Accelerated Phase of MPN: What It Is and What to Do About It
Progression of Philadelphia-chromosome negative myeloproliferative neoplasms (MPNs) to the accelerated phase (AP) or blast phase (BP) is associated with poor outcomes. As our understanding of the molecular drivers of MPN progression has grown, there has been increasing investigation into the use of novel targeted approaches in the treatment of these diseases. In this review we summarize the clinical and molecular risk factors for progression to MPN-AP/BP followed by discussion of treatment approach. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 25, 2023 Category: Hematology Authors: Anand A. Patel, Olatoyosi Odenike Tags: Review Article Source Type: research